Outpatient visit (subsequent), GP Values not sampled visit, Full blood independently but n/a n/a n/a count, ESR, LFT, linked to outpatient U&E , Chest X-ray visit sample tests Inpatient cost 240 48.00 Infusion 171 34.27 Lognormal administration CIs are derived by Home visit 27 5.40 assuming lower and upper limits are Proportion of ±20% of the mean patients that value require a nurse visit 0.1 0.02 Beta for subcutaneous injection CIs are derived by Average annual assuming lower and income of the 26989 2698.90 upper limits are Lognormal population (indirect ±10% of the mean cost) value Based on NHS AE (pneumonia) 2047 37.26 Normal reference costs [7] CIs are derived by assuming lower and AE (palliative care) 314.17 62.83 upper limits are Lognormal ±20% of the mean value bDMARDs 0.986 0.0036 Assumes upper limit of CI=1 (no disutility), sDMARDs 0.970032841 0.0076 and the respective AE disutility Beta mean is used to Palliative care 0.0076 create an acceptable 0.970032841 range. Certolizumab pegol 0.113 0.0742 AE event bDMARD (excluding Singh et al. 2012 [6] Beta probabilities 0.035 0.0048 certolizumab pegol) Based on the variance covariance Treatment Discontinuation derived from Multinomial 0 1 Discontinuation (Loglogistic model) treatment Normal discontinuation analysis (Appendix B) ACR, American College of Rheumatology; AE, adverse event; American College of Rheumatology, ACR; bDMARDs, biologic disease modifying anti-rheumatic drug; CI, confidence interval; ESR, erythrocyte sedimentation rate; GP, general practitioner; HAQ, Health Assessment Questionnaire; LFT, liver function test; N, sample size; n/a, not applicable; sDMARD, synthetic disease modifying anti-rheumatic drug; U&E , urea and electrolytes; VAS, visual analogue scale
Outpatient visit (subsequent), GP visit, Full blood count, ESR, LFT, U&E , Chest X-ray tests n/a n/a Values not sampled independently but linked to outpatient visit sample n/a Inpatient cost 240 48.00 CIs are derived by assuming lower and upper limits are ±20% of the mean value Lognormal Infusion administration 171 34.27 Home visit 27 5.40 Proportion of patients that require a nurse visit for subcutaneous injection 0.1 0.02 Beta Average annual income of the population (indirect cost) 26989 2698.90 CIs are derived by assuming lower and upper limits are ±10% of the mean value Lognormal AE (pneumonia) 2047 37.26 Based on NHS reference costs [7] Normal AE (palliative care) 314.17 62.83 CIs are derived by assuming lower and upper limits are ±20% of the mean value Lognormal AE disutility bDMARDs 0.986 0.0036 Assumes upper limit of CI=1 (no disutility), and the respective mean is used to create an acceptable range. Beta sDMARDs 0.970032841 0.0076 Palliative care 0.970032841 0.0076 AE event probabilities Certolizumab pegol 0.113 0.0742 Singh et al. 2012 [6] Beta bDMARD (excluding certolizumab pegol) 0.035 0.0048 Treatment Discontinuation Discontinuation (Loglogistic model) 0 1 Based on the variance covariance derived from treatment discontinuation analysis (Appendix B) Multinomial Normal ACR, American College of Rheumatology; AE, adverse event; American College of Rheumatology, ACR; bDMARDs, biologic disease modifying anti-rheumatic drug; CI, confidence interval; ESR, erythrocyte sedimentation rate; GP, general practitioner; HAQ, Health Assessment Questionnaire; LFT, liver function test; N, sample size; n/a, not applicable; sDMARD, synthetic disease modifying anti-rheumatic drug; U&E , urea and electrolytes; VAS, visual analogue scale
40273_2014_165_MOESM5_ESM.docx